nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist (ab120078)
Key features and details
- Potent and selective κ opioid receptor antagonist
- CAS Number: 113158-34-2
- Purity: > 98%
- Soluble in water to 50 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
nor-Binaltorphimine (nor-BNI), kappa opioid receptor antagonist -
製品の詳細
Potent and selective κ opioid receptor antagonist -
別名
- nor-BNI
-
生理活性の詳細
Potent and selective κ opioid receptor antagonist
-
精製度
> 98% -
CAS 番号
113158-34-2 -
構造式
製品の特性
-
体系名
17,17'-(Dicyclopropylmethyl)-6,6',7,7'-6,6'-imino-7,7'-binorphinan-3,4',14,14'-tetrol dihydrochloride -
分子量
734.72 -
分子式
C40H43N3O6.2HCl -
PubChem 登録番号
11957626 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in water to 50 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl -
由来
Synthetic
-
研究分野
画像
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (9)
ab120078 は 9 報の論文で使用されています。
- Makino Y et al. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol 5:299 (2022). PubMed: 35365763
- Huang H et al. Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats. Pain Res Manag 2022:4819910 (2022). PubMed: 35646201
- Barbaro JM et al. Morphine disrupts macrophage functions even during HIV infection. J Leukoc Biol 112:1317-1328 (2022). PubMed: 36205434
- Wei YY et al. Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion. Acta Pharmacol Sin 43:1372-1382 (2022). PubMed: 34493813
- Zhai FJ et al. Involvement of Opioid Peptides in the Analgesic Effect of Spinal Cord Stimulation in a Rat Model of Neuropathic Pain. Neurosci Bull 38:403-416 (2022). PubMed: 35397112
- He Y et al. Transgenic increase in the ß-endorphin concentration in cerebrospinal fluid alleviates morphine-primed relapse behavior through the µ opioid receptor in rats. J Med Virol 91:1158-1167 (2019). PubMed: 30701563
- Sun J et al. Salvinorin A attenuates early brain injury through PI3K/Akt pathway after subarachnoid hemorrhage in rat. Brain Res 1719:64-70 (2019). PubMed: 31125530
- Azocar VH et al. The blocking of kappa-opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization. J Neurochem 148:348-358 (2019). PubMed: 30315655
- Li TF et al. Ester Hydrolysis Differentially Reduces Aconitine-Induced Anti-hypersensitivity and Acute Neurotoxicity: Involvement of Spinal Microglial Dynorphin Expression and Implications for Aconitum Processing. Front Pharmacol 7:367 (2016). PubMed: 27761113